Electromedical Technologies Announces Financial and Operational Highlights for the Three Months Ended March 31, 2022

Rhea-AI Summary

Electromedical Technologies, Inc. (OTCQB: EMED) reported strong Q1 2022 financials, with net sales rising by 33% year-over-year to $221,894. Gross profit also increased by 24%, though gross margin decreased from 75% to 70% due to higher freight costs. The company's net loss dropped significantly by 55% to $1.1 million. Electromedical continues to invest in marketing and sales and has recently hired a new Director of Business and Sales Development to support growth. The launch of a new product line is anticipated in October 2022.

Positive

• Net sales increased 33% year over year to $221,894.
• Gross profit increased 24% year over year.
• Net loss reduced by 55% year over year to $1.1 million.
• Continued investments in marketing and sales personnel.

Negative

• Gross margin decreased from 75% to 70% due to increased freight costs.

SCOTTSDALE, Ariz., May 24, 2022 /PRNewswire/ -- InvestorsHub NewsWire -- Electromedical Technologies, Inc. (OTCQB: EMED) ("Electromedical" or the "Company"), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable, and acute pain by using frequencies and electro-modulation, is pleased to provide its Financial and Operational Highlights for the three months ended March 31, 2022.

"We continue to drive strong growth on the topline, which is critical given the inherent scalability of our model and our capacity to expand with strong margins," noted Matthew Wolfson, Founder and CEO of Electromedical. "Our flagship device, the WellnessPro plus, has helped thousands upon thousands of people over the past 15 years get their lives back and enjoy a pain free life without the use of opioids. These trends are picking up in our core business and our focus on investing in marketing and sales personnel and initiatives continues to pay off and provide a strong outlook ahead as we move closer toward the commercial launch of our next generation product line."

Financial Performance Highlights for the Three Months Ended Mar 31, 2022

• Net Sales increased 33% year over year to $221,894
• Gross Profit increased 24% year over year
• Gross Margin decreased from 75% to 70%, impacted by additional freight costs to expedite inventory delivery
• Overall Net Loss dropped 55% year over year to $1.1 million

Operational Highlights for the Three Months Ended Mar 31, 2022

• Continued investments in Marketing and Sales initiatives.
• Hired Director of Business and Sales Development with deep industry track record and experience.
• Made strong R&D gains in development of new product line targeting October 2022 full commercial launch.

Management sees the Company's continued strides in topline growth as further reinforcement for its strategic decision to invest heavily in sales and marketing, both in terms of personnel and other key strategies. In particular, the Company's decision to hire a top industry veteran with a long track record of success, David Orn, as its new Director of Business and Sales Development has been important in driving further topline expansion.

Orn added, "My goal for this year is to onboard  100 active independent medical sales reps, selling the Wellness Pro plus every month."

Wolfson added, "Q1 was a strong start to an exciting year with bold steps ahead. I'm proud of our team and grateful for the new talent we have been adding as we scale our operations, and I look forward to sharing more with our stakeholders as we push past new milestones in the months ahead."

About Electromedical Technologies

Headquartered in Scottsdale, Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through University collaboration agreements, the Company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body. By studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses, the Company's goal is to reduce pain and improve overall human wellbeing. The Company's current FDA cleared product indications are for chronic acute post-traumatic and post-operative, intractable pain relief. 

For more information, please visit www.electromedtech.com.

Note: Nonhuman preliminary studies that we are planning to start in the near future and their applications are not related to our current product in any way and are currently not cleared in the US.

Safe Harbor Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

Corporate Contact:

Electromedical Technologies, Inc.
Tel: 1.888.880.7888
Email: ir@electromedtech.com
https://electromedtech.com

 

ELECTROMEDICAL TECHNOLOGIES, INC. BALANCE SHEETS (UNAUDITED)
		March 31, 2022			December 31,  2021
ASSETS
Current assets:
Cash and cash equivalents		$	170,048		$	383,170
Accounts receivable			31,790			35,085
Inventories			196,924			218,510
Prepaid expenses and other current assets			24,930			38,002
Total current assets			423,692			674,767
Property and equipment, net			721,875			727,344
Total assets		$	1,145,567		$	1,402,111
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current liabilities:
Accounts payable		$	274,251		$	214,785
Credit cards payable			14,686			11,283
Accrued expenses and other current liabilities			539,237			317,037
Customer deposits			21,850			—
Convertible promissory notes, net of discount of $492,877 and $723,166, respectively			1,289,476			811,687
Related party notes payable			—			57,875
Long term debt, current portion			30,490			29,502
Total current liabilities			2,169,990			1,442,169
Long-term liabilities:
Bank debt, net of current portion			511,613			518,849
Government debt, net of current portion			153,789			154,429
Other liabilities			9,204			9,167
Total liabilities			2,844,596			2,124,614
Commitments and contingencies			—			—
Stockholders' deficit
Series A Preferred Stock, $.00001 par value, 1,000,000 shares authorized and 500,000 outstanding			355,000			355,000
Series B Preferred Stock, $.00001 par value, 1 share authorized and 0 outstanding			—			—
Common stock, $.00001 par value, 500,000,000 and 250,000,000 shares authorized; 104,955,567 and 87,725,842 shares outstanding at March 31, 2022 and December 31, 2021, respectively			1,048			876
Additional paid-in-capital			20,401,493			20,804,333
Accumulated deficit			(22,456,570)			(21,882,712)
Total stockholders' deficit			(1,699,029)			(722,503)
Total liabilities and stockholders' deficit		$	1,145,567		$	1,402,111

 

 

ELECTROMEDICAL TECHNOLOGIES, INC. STATEMENTS OF OPERATIONS FOR THE THREE MONTHS ENDED MARCH 31, (UNAUDITED)
		2022			2021
Net sales		$	221,894		$	166,440
Cost of sales			67,641			41,951
Gross profit			154,253			124,849
Selling, general and administrative expenses			879,810			1,689,383
Loss from operations			(725,557)			(1,564,534)
Other income (expense)
Interest expense			(213,379)			(1,060,302)
Change in fair market value of derivative liabilities			—			14,798
Other income (expense)			—			(428)
Loss on extinguishment of debt			(205,600)			—
Forgiveness of debt			—			50,082
Total other expense			(418,979)			(995,850)
Net loss		$	(1,144,536)		$	(2,560,384)
Deemed dividend related to warrant resets			(63,381)			(510,222)
Net loss attributable to common stockholders			(1,207,917)			(3,070,606)
Weighted average shares outstanding - basic and diluted			97,260,915			28,558,027
Weighted average loss per share - basic and diluted		$	(0.01)		$	(0.11)

 

ELECTROMEDICAL TECHNOLOGIES, INC. STATEMENTS OF CASH FLOWS FOR THE THREE MONTHS ENDED MARCH 31, (UNAUDITED)
		2022			2021
Cash flows from operating activities:
Net loss		$	(1,144,536)		$	(2,560,384)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense			361,603			1,298,727
Depreciation and amortization			5,469			5,469
Forgiveness of debt			—			(49,783)
Loss on extinguishment of debt			205,600			—
Amortization of debt discount and day one derivative loss and warrant expense			164,710			1,010,601
Change in fair value of derivative liabilities- convertible promissory notes			—			(14,798)
Change in operating assets and liabilities:
Accounts receivable			3,295			(4,178)
Inventories			21,586			(129,791)
Prepaid expenses and other current assets			13,072			161,990
Other assets			—			7,000
Accounts payable			59,466			(42,284)
Credit cards payable			3,403			(1,057)
Accrued expenses and other current liabilities			(33,400)			9,817
Customer deposits			21,850			(18,301)
Other liabilities			37			(265)
Net cash used in operating activities			(317,845)			(327,237)
Cash flows from financing activities:
Repayments on bank debt			(6,888)			(6,556)
Related party notes payable-net			(57,875)			(50,000)
Issuance of convertible promissory notes			494,220			712,500
Repayments on convertible promissory notes			(367,500)			—
Repayments on notes payable			—			(12,846)
Issuance of common stock for cash - net			42,766			—
Net cash provided by financing activities			104,723			643,098
Net (decrease) increase in cash and cash equivalents			(213,122)			315,861
Cash and cash equivalents, beginning of period			383,170			264,913
Cash and cash equivalents, end of period		$	170,048		$	580,774
Supplemental disclosures of cash flow information:
Cash paid during the period for:
Interest		$	72,308		$	16,356
Income taxes		$	—		$	—
Non-cash investing and financing activities:
January 1,2022 adoption of ASU2020-06		$	379,355		$	—
Warrants, common stock and beneficial conversion feature issued in conjunction with convertible promissory notes		$	192,996		$	420,096
Derivative liabilities issued in conjunction with convertible promissory notes		$	—		$	974,931
Conversion of convertible promissory notes, derivative liabilities and accrued interest into shares of common stock		$	—		$	380,103

 

View original content:https://www.prnewswire.com/news-releases/electromedical-technologies-announces-financial-and-operational-highlights-for-the-three-months-ended-march-31-2022-301553584.html

SOURCE Electromedical Technologies, Inc.

FAQ

What were the financial highlights for Electromedical Technologies in Q1 2022?

Electromedical reported a 33% increase in net sales to $221,894 and a 24% rise in gross profit, though gross margin dropped from 75% to 70%.

What is the current net loss of Electromedical Technologies as of March 31, 2022?

The net loss for Q1 2022 was $1.1 million, a reduction of 55% year over year.

When is Electromedical's next generation product line expected to launch?

The new product line is anticipated to launch in October 2022.

What strategic investments is Electromedical making for growth?

Electromedical is investing heavily in marketing and sales initiatives, including hiring new personnel.